Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Conditions
Multiple Myeloma
Phase I
Volunteers
Health Professionals
What is the purpose of this trial?
The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.
- Trial withYale University
- Start Date02/21/2022
- End Date08/01/2023
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Adam Boruchov, MD
- Agatha Hecht
- Alexis Walker
- Andrea Brennan
- Andrea Martelli
- Anna Fleischman
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS
- Benjamin Newton, MD
- Beverly Drucker, MD, PhD
- Brooke Chaves
- Carrie Fijal, MSN, AGPCNP-BC, OCN
- D. Barry Boyd, MD, MS
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Erica Stevens
- Francesca Montanari, MD
- Gloria Huang, MD, FACOG
- Harold Tara Jr, MD
- Iris Isufi, MD
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jason Haldas, MD
- Jaykumar Thumar, MBBS, MD
- Jeremy Kortmansky, MD
- Johanna LaSala, MD
- Justin Persico, MD
- Katherine Harvey, MD, MPH
- Kathleen Fenn, MD
- Kelsey Martin, MD
- Kert Sabbath, MD, FACP
- Kristen Hoxie
- M. Sung Lee, MD
- Madeline Santiago
- Michael Cohenuram, MD
- Neal Fischbach, MD
- Nicholas Blondin, MD
- Noffar Bar, MD
- Pawan Karanam, MD
- Robert Legare, MD
- Sabrina Browning, MD
- Sara Anastasio, RN
- Sarah Carlson
- Stephanie Paine, APRN
- Stephen Lattanzi, MD
- Stuart Seropian, MD
- Su Hsien Lim, MD
- Sudhanshu Mulay, MD
- Susan Rabinowe, MD
- Syed Bilgrami, MBBS
- Tara Anderson
- Terri Parker, MD
- Victor Chang, MD
- Vidya Brown
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Xuanthao Thi Nguyen
- Zia Rahman, MD
- Last Updated11/11/2022
- Study HIC#2000028918